Beximco Pharmaceuticals Ltd.

13th September 2009

Beximco Pharma Donates Oseflu (Oseltamivir) capsule to ICDDR,B for Swine Flu treatment

Leading drug manufacturer Beximco Pharmaceuticals Ltd. (BPL) yesterday (September 13, 2009) donated 5000 pcs. of Oseflu (Oseltamivir) capsule to ICDDR,B as a gesture of BPL’s support for the swine flu affected community of the country. This donation was a part of BPL’s ongoing CSR activities as a response to this major public health problem.

Beximco Pharma is the pioneer in introducing Oseltamivir preparation is Bangladesh. Back in March 22, 2006, Beximco Pharma introduced Oseflu capsule for the prevention and treatment of human cases of Avian Influenza (H5N1). Besides its use in Bangladesh, Beximco Pharma also supplied Oseflu in ASEAN countries, Central America & Latin America for the treatment of Swine flu affected people.

Beximco Pharma has also started a public awareness Programme against swine flu which comprises public awareness posters, inserts, patient information guide, sticker and advertisement in the newspaper.


Regarding the donation of the drug, the Beximco Pharma′s Managing Director, Mr. Nazmul Hassan, MP, said, “Beximco Pharma always likes to work together with reputed organizations like ICDDR,B in public health related issues. Bangladesh is under great threat of facing consequences of Swine Flu and it′s everyone′s combined effort that can create a strong resistance against this deadly disease in Bangladesh.” Dr. Mark Pietroni, Medical Director of ICDDR,B also spoke on the occasion of handing over the medicine and said, “We welcome this nice gesture of Beximco Pharma that would be of great help for patients coming to us for the treatment of Swine Flu”.

As a part of its public awareness program, the company has also opened a ‘24 hour Swine flu Hotline (01711-438-139)’ for all to provide information on Swine Flu and its management.

Notes to Editors
About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff. The Company’s products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.